StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) stock

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/3025% above fair value
$9.70−0.85 (-8.06%)

Close on Nov 13, 2026Market cap $1.36BP/E –Yield –

Intellia Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Intellia Therapeutics's total assets was $902.56M at Sep 30, 2026. For fiscal 2025 it was $842.13M, down 29.3% from the year before. Over ten years it grew 26.2% a year on average. The highest annual figure on record is $1.52B in fiscal 2022.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$842.13M-29.3%
FY2024Dec 31, 2024$1.19B-8.5%
FY2023Dec 31, 2023$1.30B-14.4%
FY2022Dec 31, 2022$1.52B+17.4%
FY2021Dec 31, 2021$1.29B+91.4%
FY2020Dec 31, 2020$676.32M+102.3%
FY2019Dec 31, 2019$334.28M-3.8%
FY2018Dec 31, 2018$347.32M-7.7%
FY2017Dec 31, 2017$376.24M+25.8%
FY2016Dec 31, 2016$298.97M+264.0%
FY2015Dec 31, 2015$82.14M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$902.56M-2.5%
Q2 FY2026Jun 30, 2026$857.16M-4.6%
Q1 FY2026Mar 31, 2026$758.78M-23.1%
Q4 FY2025Dec 31, 2025$842.13M-29.3%
Q3 FY2025Sep 30, 2025$925.28M-21.1%
Q2 FY2025Jun 30, 2025$898.89M-24.6%
Q1 FY2025Mar 31, 2025$986.16M-21.7%
Q4 FY2024Dec 31, 2024$1.19B-8.5%
Q3 FY2024Sep 30, 2024$1.17B-5.6%
Q2 FY2024Jun 30, 2024$1.19B-10.0%
Q1 FY2024Mar 31, 2024$1.26B-11.2%
Q4 FY2023Dec 31, 2023$1.30B-14.4%
Q3 FY2023Sep 30, 2023$1.24B+14.7%
Q2 FY2023Jun 30, 2023$1.32B+19.2%
Q1 FY2023Mar 31, 2023$1.42B+17.9%
Q4 FY2022Dec 31, 2022$1.52B+17.4%
Q3 FY2022Sep 30, 2022$1.08B-18.8%
Q2 FY2022Jun 30, 2022$1.11B+65.2%
Q1 FY2022Mar 31, 2022$1.20B+67.8%
Q4 FY2021Dec 31, 2021$1.29B+91.4%
Q3 FY2021Sep 30, 2021$1.33B+191.1%
Q2 FY2021Jun 30, 2021$672.24M+37.0%
Q1 FY2021Mar 31, 2021$716.89M+127.8%
Q4 FY2020Dec 31, 2020$676.32M+102.3%
Q3 FY2020Sep 30, 2020$458.56M+32.3%
Q2 FY2020Jun 30, 2020$490.83M+39.3%
Q1 FY2020Mar 31, 2020$314.75M-8.6%
Q4 FY2019Dec 31, 2019$334.28M-3.8%
Q3 FY2019Sep 30, 2019$346.64M+7.9%
Q2 FY2019Jun 30, 2019$352.44M+3.7%
Q1 FY2019Mar 31, 2019$344.36M-4.2%
Q4 FY2018Dec 31, 2018$347.32M-7.7%
Q3 FY2018Sep 30, 2018$321.23M+28.9%
Q2 FY2018Jun 30, 2018$339.78M+28.2%
Q1 FY2018Mar 31, 2018$359.55M+28.7%
Q4 FY2017Dec 31, 2017$376.24M+25.8%
Q3 FY2017Sep 30, 2017$249.17M–
Q2 FY2017Jun 30, 2017$264.98M–
Q1 FY2017Mar 31, 2017$279.26M–
Q4 FY2016Dec 31, 2016$298.97M–

More Intellia Therapeutics figures

See a number that looks wrong?